CCND1 polyclonal (C-term T286), anti-human

Background:
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.

Other Names:
G1/S-specific cyclin-D1, B-cell lymphoma 1 protein, BCL-1, BCL-1 oncogene, PRAD1 oncogene, CCND1, BCL1, PRAD1

Target/Specificity:
This CCND1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 264-292 amino acids from the C-terminal region of human CCND1.

Antigen Region:
264-292

Antigen Type: Synthetic Peptide

Gene Name: CCND1 {ECO:0000303|PubMed:8204893, ECO:0000312|HGNC:HGNC:1582}
Gene ID: 595
Primary Accession: P24385
NCBI Accession: NP_444284.1
Other Accession: Q2KI22; Q6FI00
Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.